Effectiveness of erlotinib treatment in advanced KRAS mutation-negative lung adenocarcinoma patients: Results of a multicenter observational cohort study (MOTIVATE)SAROSI, Veronika; LOSONCZY, Gyorgy; FRANCOVSZKY, Eva et al.Lung cancer. 2014, Vol 86, Num 1, pp 54-58, issn 0169-5002, 5 p.Article

Pathologie und Molekular-biologie gastrointestinaler Stromatumoren (GIST) : GIST Gastrointestinal stromal tumors = Pathology and molecular biology of gastrointestinal stromal tumors (GIST)SCHILDHAUS, H.-U; MERKELBACH-BRUSE, S; BÜTTNER, R et al.Der Radiologe (Berlin. Print). 2009, Vol 49, Num 12, pp 1104-1108, issn 0033-832X, 5 p.Article

Dichotomy in NF-_KB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggeringTROMP, J. M; TONINO, S. H; ELIAS, J. A et al.Oncogene (Basingstoke). 2010, Vol 29, Num 36, pp 5071-5082, issn 0950-9232, 12 p.Article

The biology of epidermal growth factor receptor and its value as a prognostic/predictive factorDEI TOS, A. P.The International journal of biological markers. 2007, Vol 22, Num 1, issn 0393-6155, S3-S9, SUP4Article

Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocationOSCIER, David; WADE, Rachel; DAVIS, Zadie et al.Haematologica (Roma). 2010, Vol 95, Num 10, pp 1705-1712, issn 0390-6078, 8 p.Article

Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genesVANURA, Katrina; LE, Trang; SCHWARZINGER, Ilse et al.Haematologica (Roma). 2008, Vol 93, Num 12, pp 1912-1916, issn 0390-6078, 5 p.Article

Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd ζ-associated protein (ZAP-70)SCHADE, Ulrika; BOCK, Oliver; VORNHUSEN, Sylke et al.Human pathology. 2006, Vol 37, Num 9, pp 1153-1161, issn 0046-8177, 9 p.Article

The effect of immunoglobulin V_H gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemiaFRANCIS, Sebastian; KARANTH, Mamatha; PRATT, Guy et al.Cancer. 2006, Vol 107, Num 5, pp 1023-1033, issn 0008-543X, 11 p.Article

Systemic treatment of patients with gastrointestinal stromal tumor : Current status and future opportunitiesDEMETRI, George D; JOENSUU, Heikki.European journal of cancer. Supplement (1990). 2008, Vol 6, Num 1, pp 1-14, issn 1359-6349, 14 p.Article

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancerAHN, Myung-Ju; CHIH-HSIN YANG, James; JUN LIANG et al.Lung cancer. 2012, Vol 77, Num 2, pp 346-352, issn 0169-5002, 7 p.Article

The Role of B Cell Receptor Stimulation in CLL Pathogenesis : The Importance of Rational Chemotherapy of Chronic Lymphocytic LeukemiaKIL, Laurens P; YUVARAJ, Saravanan; LANGERAK, Anton W et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 23, pp 3335-3355, issn 1381-6128, 21 p.Article

The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemiaKADERI, M. A; NORBERG, M; ROSENQUIST, R et al.Leukemia. 2008, Vol 22, Num 2, pp 339-343, issn 0887-6924, 5 p.Article

Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patientsRICCA, I; ROCCI, A; CALVI, R et al.Leukemia. 2007, Vol 21, Num 4, pp 697-705, issn 0887-6924, 9 p.Article

Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancerOKAMOTO, Isamu; AOE, Keisuke; OKAMOTO, Hiroaki et al.Investigational new drugs. 2013, Vol 31, Num 5, pp 1275-1282, issn 0167-6997, 8 p.Article

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findingsKUBICKA, S; GREIL, R; MAKRUTZKI, M et al.Annals of oncology. 2013, Vol 24, Num 9, pp 2342-2349, issn 0923-7534, 8 p.Article

Potential tumorigenic programs associated with TP53 mutation status reveal role of VEGF pathwayJOSHI, H; BHANOT, G; BØRRESEN-DALE, A.-L et al.British journal of cancer. 2012, Vol 107, Num 10, pp 1722-1728, issn 0007-0920, 7 p.Article